New combo therapy tested for Tough-to-Treat cancers
Disease control
Completed
This study tested whether adding an experimental drug called TJ004309 to an existing immunotherapy (atezolizumab) could help control advanced cancers that have stopped responding to standard treatments. It involved 25 patients with specific types of advanced solid tumors, includi…
Phase: PHASE2 • Sponsor: I-Mab Biopharma US Limited • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC